Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in Stage III and bulky Stage II nonseminomatous testicular cancer

G. Pizzocaro, R. Salvioni, M. Pasi, F. Zanoni, A. Milani, S. Pilotti, S. Monfardini

Research output: Contribution to journalArticle

Abstract

Sixty consecutive patients with Stage III or bulky Stage II nonseminomatous germinal testis tumors were treated with cisplatin, vinblastine, bleomycin combination chemotherapy (PVB). One patient died of acute toxicity after the first course of therapy, 16 entered complete remission (CR) after two or three inductions, and 36 underwent surgery for removal of residual masses after the third cycle. No residual tumor was found in 16 cases, 10 had mature teratoma, and residual malignant tumor was completely resected in 8 of 10 patients. On the whole, 52 of 59 cases (88%) who completed the therapy entered CR, 34 (58%) with PVB and 18 (30%) with PVB and resection of the residual disease. The major beneficiaries of surgery were patients with bulky metastases (17 of 45, 38%) and those with primary teratocarcinoma (13 of 24, 54%). All of the patients who entered CR received two additional inductions and no maintenance. After a median follow-up period of >3 years, 40 patients (68%) remain continuously disease-free, 1 died in CR, and 3 of the 11 who had relapse were salvaged. All of the 32 patients with lung deposits

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalCancer
Volume56
Issue number2
DOIs
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in Stage III and bulky Stage II nonseminomatous testicular cancer'. Together they form a unique fingerprint.

  • Cite this